Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review. (2nd December 2018)

• Record Type: Journal Article
• Authors: Crawford, James J.; Bronner, Sarah M.; Zbieg, Jason R.
• Is Part Of: Expert opinion on therapeutic patents. Volume 28:Number 12(2018)
• Page Start: 867
• Page End: 873
• Publication Date: 2018-12-02
• Subjects: Hippo pathway -- YAP -- TEAD -- TAZ; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2018.1549226
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : The Hippo pathway represents a new and intriguing opportunity for the treatment of cancer. Activation or overexpression of Yes-associated protein (YAP) or transcriptional coactivator with PDZ-binding motif (TAZ) has been shown to lead to cell transformation and tumor development. To date, no small molecule compounds targeting this pathway have progressed to the clinic, illustrating both its potential and its infancy. Areas covered : The present review seeks to summarize published patent applications from assignee companies that have disclosed direct small molecule inhibitors of the YAP/TAZ–transcriptional enhanced associate domain (TEAD) interaction. Expert opinion : The Hippo pathway, and specifically the YAP/TAZ–TEAD transcriptional complex, has been shown to be a promising target for the treatment of cancer. However, reports in the area of small molecules targeting the YAP/TAZ–TEAD transcriptional activation complex are few and far between, with only two published patent applications that disclose compounds with moderate levels of pathway inhibition. Interestingly, the YAP/TAZ–TEAD complex can be disrupted through two very different mechanisms, one of which is direct inhibition at either the Ω-loop or the α-helix of the YAP–TEAD binding interface. Both YAP protein segments have been shown to be important to TEAD binding. Alternatively, it has been reported that allosteric inhibition might be accomplished by binding the TEAD palmitoylation pocket, thus disrupting YAP binding and also native protein stabilization. The advantages and liabilities of disrupting the YAP/TAZ–TEAD complex through these two distinct mechanisms have yet to be fully elucidated, and it remains unclear which approach, if any, will generate the first clinical stage inhibitor of the Hippo pathway.